The ADCY1-mediated cAMP signaling pathway mediates functional effects of montelukast treatment in brain organoids
Open Access
- 5 June 2025
- journal article
- research article
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 82 (1) , 1-14
Abstract
Montelukast (MTK) is a drug widely used for treating allergic rhinitis and asthma. However, severe neuropsychiatric adverse events related to MTK have been reported, with limited understanding of the underlying mechanisms. Here we leveraged human forebrain organoids (hFOs) and showed that MTK exposure in hFOs downregulated the expression of genes associated with multiple neuronal functions and neuropsychiatric disorders. The following integrative analysis highlighted adenylate cyclase 1 (ADCY1), a main regulator of the cAMP signaling pathway, as a hub gene mediating the functional effects of MTK exposure. We also showed that MTK exposure resulted in a reduction of cAMP and neuroactivities, and caused neural maturation defects. These cellular phenotypes could be recapitulated by treating hFOs with ST034307, a selective ADCY1 inhibitor, or partially rescued by ADCY1 overexpression in hFOs. Together, this study underscored that MTK exposure caused neuropsychiatric effects through inhibiting the ADCY1-mediated cAMP signaling pathway.Keywords
Funding Information
- National Natural Science Foundation of China (82171504, 81901359)
- Natural Science Foundation of Hunan Province (2022JJ20035)
- science and technology innovation Program of Hunan Province (2022RC1214)
This publication has 44 references indexed in Scilit:
- The mechanisms underlying montelukast's neuropsychiatric effects - new insights from a combined metabolic and multiomics approachLife Sciences, 2022
- Analysis of Neuropsychiatric Diagnoses After Montelukast InitiationJAMA Network Open, 2022
- A Boxed Warning for Montelukast: The FDA PerspectiveThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- In vitro cytotoxicity of montelukast in HAPI and SH-SY5Y cellsChemico-Biological Interactions, 2020
- Transcriptomic Landscape and Functional Characterization of Induced Pluripotent Stem Cell–Derived Cerebral Organoids in SchizophreniaJAMA Psychiatry, 2020
- The Leukotriene Receptor Antagonist Montelukast Reduces Alpha-Synuclein Load and Restores Memory in an Animal Model of Dementia with Lewy BodiesNeurotherapeutics, 2020
- Montelukast and Neuropsychiatric Events in Children with Asthma: A Nested Case–Control StudyThe Journal of Pediatrics, 2019
- Montelukast attenuates rotenone-induced microglial activation/p38 MAPK expression in rats: Possible role of its antioxidant, anti-inflammatory and antiapoptotic effectsToxicology and Applied Pharmacology, 2018
- FOXG1-Dependent Dysregulation of GABA/Glutamate Neuron Differentiation in Autism Spectrum DisordersCell, 2015
- Rapid Single-Step Induction of Functional Neurons from Human Pluripotent Stem CellsNeuron, 2013